Brought to you by 
Moderna raises $560mm in Series G round
15 Nov 2018
Executive Summary
Moderna Therapeutics LLC (mRNA therapeutics) raised $560mm in its Series G financing round consisting of 55.7mm preferred shares at $10.06. New US and international investors Abu Dhabi Investment Authority, BB Biotech AG, Julius Baer, Singapore-based EDBI, and Sequoia Capital China joined existing investors Fidelity Management & Research, Pictet, Viking Global Investors, ArrowMark Partners, and Alexandria Venture Investments. The company will use the funds to continue to execute on its pipeline (19 development candidates including 10 in clinical trials); for drug discovery in rare diseases and prophylactic vaccines; for investment in mRNA science and technology; and for investment in manufacturing infrastructure and digital backbone.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Pulmonary
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Moderna raises $560mm in Series G round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice